Cardiology in Review最新文献_第2页

Long-Term Oxygen Therapy and Cardiovascular Physiology: Divergent Effects in Heart Failure and Pulmonary Hypertension. 长期氧疗和心血管生理学：心力衰竭和肺动脉高压的不同作用。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-06 DOI: 10.1097/CRD.0000000000001295

Josef Kusayev, Shrikant Nayak, William H Frishman, Wilbert S Aronow

{"title":"Long-Term Oxygen Therapy and Cardiovascular Physiology: Divergent Effects in Heart Failure and Pulmonary Hypertension.","authors":"Josef Kusayev, Shrikant Nayak, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000001295","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001295","url":null,"abstract":"Long-term oxygen therapy (LTOT) is a cornerstone of management for chronic hypoxemic respiratory diseases, such as chronic obstructive pulmonary disease, yet its physiological impact as a potent modulator of cardiovascular function remains a subject of ongoing investigation. While oxygen is primarily prescribed to correct arterial desaturation, its role as a regulator of vascular tone and cellular metabolism suggests it can exert significant, and sometimes contrasting, effects on the heart and systemic circulation. This review evaluates the evidence for LTOT in heart failure and pulmonary hypertension, 2 conditions where oxygen is frequently utilized despite varying levels of baseline hypoxemia. In heart failure, LTOT has not been shown to improve key hemodynamic variables and relevant endpoints, such as exercise capacity, in normoxemic patients. Some studies suggest that supplemental oxygen may even impose hemodynamic strain in this population by increasing systemic vascular resistance and reducing cardiac output. On the other hand, LTOT shows promise in improving relevant hemodynamic variables in pulmonary hypertension, such as mean pulmonary arterial pressure, as well as exercise capacity and other clinical measures across various baseline oxygen saturation levels. These findings suggest that the cardiovascular response to LTOT is highly dependent on the specific underlying pathology.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why Do Blue Zone Populations Live Longer? Mechanistic Insights Into Cardiovascular Longevity. 为什么蓝区人口寿命更长？心血管寿命的机制洞察。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-06 DOI: 10.1097/CRD.0000000000001291

Kartik Mehta, Arihant Senthil, Himanshi Banker, Yash Vardhan Trivedi, Anush Manucharyan, Nitasa Sahu, Rohit Jain

{"title":"Why Do Blue Zone Populations Live Longer? Mechanistic Insights Into Cardiovascular Longevity.","authors":"Kartik Mehta, Arihant Senthil, Himanshi Banker, Yash Vardhan Trivedi, Anush Manucharyan, Nitasa Sahu, Rohit Jain","doi":"10.1097/CRD.0000000000001291","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001291","url":null,"abstract":"Growing interest in Blue Zone populations and a focus on cardiovascular protection are leading to significant discoveries about human longevity. These regions-Okinawa, Sardinia, the Nicoya Peninsula, Ikaria, and Loma Linda-are characterized by a high prevalence of centenarians and relatively low rates of cardiovascular mortality. Despite cardiovascular disease remaining the leading global cause of morbidity and mortality, its relationship with exceptional longevity remains incompletely understood. Much of the existing literature on Blue Zones is descriptive, with limited integration of cardiovascular epidemiology and the biological mechanisms underlying healthy cardiac aging. This narrative review aims to bridge this gap by examining key cardiovascular features associated with longevity, including vascular aging, myocardial remodeling, and autonomic regulation. In addition, we explore mechanistic pathways derived from centenarian studies, such as reduced inflammation, enhanced metabolic efficiency, and favorable neurohormonal balance, to better understand how these factors collectively shape a distinct cardiovascular aging trajectory. By integrating epidemiological patterns with mechanistic insights, this work seeks to provide a more comprehensive framework for understanding cardiovascular longevity and its potential translation into preventive cardiology.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Cardiopulmonary Complications of Vaping. 电子烟的心肺并发症。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-04 DOI: 10.1097/CRD.0000000000001280

Ariel Milshteyn, Victor Del Rio, Andrew M Treihaft, Jeremy A Weingarten, Anthony G Saleh, Ruth Minkin, William H Frishman, Stephen J Peterson

{"title":"The Cardiopulmonary Complications of Vaping.","authors":"Ariel Milshteyn, Victor Del Rio, Andrew M Treihaft, Jeremy A Weingarten, Anthony G Saleh, Ruth Minkin, William H Frishman, Stephen J Peterson","doi":"10.1097/CRD.0000000000001280","DOIUrl":"https://doi.org/10.1097/CRD.0000000000001280","url":null,"abstract":"Electronic cigarettes, also known as e-cigarettes or vapes, have risen in popularity recently, especially among teenagers and young adults, because many believe they are safer than regular cigarettes. However, research has shown that the use of e-cigarettes can still lead to significant pulmonary and cardiovascular risks. E-liquids usually contain propylene glycol, vegetable glycerin, nicotine, flavorings, and sometimes tetrahydrocannabinol or other additives. When these ingredients are heated, they can produce harmful chemicals such as reactive aldehydes and other toxins that cause inflammation and other long-term effects. Studies have found a positive correlation between the use of e-cigarettes and oxidative stress, inflammation, and endothelial damage. Research has also linked vaping to an increase of reactive oxygen species in the blood of people like those of traditional tobacco smokers. The 2019-2020 outbreak of e-cigarette or vaping-associated lung injury, which was strongly connected to the unregulated presence of tetrahydrocannabinol and vitamin E acetate, highlighted the serious risks of these products. Our aim is to examine the health and economic burdens posed by e-cigarette use and challenge the idea that they are a \"safer\" alternative to traditional tobacco smoking.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Landiolol for Treating Arrhythmias: A State-of-The-Art Review. 治疗心律失常的兰地洛尔：最新研究综述

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-03-13 DOI: 10.1097/CRD.0000000000000687

Muhammad Ghallab, Mahmoud Samy Ahmed, Talia H Ostrow, Muhammad Haseeul Rasool, Zakaria Alagha, Daniel Miller, William H Frishman, Wilbert S Aronow, Daniel Frenkel

{"title":"Landiolol for Treating Arrhythmias: A State-of-The-Art Review.","authors":"Muhammad Ghallab, Mahmoud Samy Ahmed, Talia H Ostrow, Muhammad Haseeul Rasool, Zakaria Alagha, Daniel Miller, William H Frishman, Wilbert S Aronow, Daniel Frenkel","doi":"10.1097/CRD.0000000000000687","DOIUrl":"10.1097/CRD.0000000000000687","url":null,"abstract":"This article provides a state-of-the-art review on landiolol, a medication that was recently submitted for 7 approvals. Focusing on its pharmacology, pharmacokinetics, and pharmacodynamics, the analysis underscores landiolol's unique attributes compared to conventional beta-blockers, particularly esmolol. As a sympatholytic agent, landiolol exhibits a short half-life, high cardioselectivity, and minimal impact on blood pressure, setting it apart in the realm of arrhythmia treatment. The review explores landiolol's potential applications, emphasizing scenarios where other beta-blockers may be limited. A detailed examination of its efficacy in preventing postoperative atrial fibrillation reveals promising results from clinical trials, suggesting its utility in diverse surgical settings. Additionally, the article delves into landiolol's role in rate control for atrial fibrillation/flutter, treatment of ventricular tachycardia/fibrillation, and its use in managing sepsis-related tachyarrhythmias. The evolving landscape of landiolol's applications extends beyond cardiac care, including potential anti-inflammatory, antioxidative, analgesic, and anticancer effects. While the outcomes from various studies are promising, challenges persist, requiring further research to optimize dosing strategies, identify optimal patient populations, and elucidate mechanisms underlying its diverse effects. The potential expansion of landiolol's applications highlights the importance of ongoing clinical investigation, offering a promising avenue for enhancing arrhythmia management and addressing broader medical needs.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"212-217"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insulin's Legacy: A Century of Breakthroughs and Innovation. 胰岛素的遗产：一个世纪的突破与创新。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-03-13 DOI: 10.1097/CRD.0000000000000680

Somar Hadid, Emily Zhang, William H Frishman, Erika Brutsaert

引用次数: 0

Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis. 治疗复发性心包炎的 Goflikicept 和相关 IL-1 抑制剂。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-05-02 DOI: 10.1097/CRD.0000000000000704

Jared M Feldman, William H Frishman, Wilbert S Aronow

{"title":"Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis.","authors":"Jared M Feldman, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000704","DOIUrl":"10.1097/CRD.0000000000000704","url":null,"abstract":"Anticytokine biologics are a promising anti-inflammatory therapy for recurrent pericarditis. Several studies have proved the efficacy and safety of interleukin-1 (IL-1) inhibitors, such as anakinra and rilonacept in patients with recurrent pericarditis. Treatment with goflikicept in a recent phase 2 and 3 trial significantly reduced the pericarditis recurrence rate compared with both the placebo and the allowed withdrawal of standard-of-care therapy. Patients with idiopathic recurrent pericarditis (IRP) achieved remission within the first 14 days of therapy. In rilonacept inhibition of interleukin-1 alpha and beta for recurrent pericarditis (phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis), rilonacept led to a significantly lower risk of pericarditis recurrence than placebo (hazard ratio, 0.04; P < 0.001) and a rapid resolution of recurrent pericarditis episodes. However, 74% of patients in the placebo group demonstrated recurrence, compared with 7% in the rilonacept group. The efficacy of anakinra was demonstrated by the AIRTRIP (anakinra-treatment of recurrent idiopathic pericarditis) trial, which showed a reduction in the incidence of recurrent pericarditis in anakinra versus placebo-treated patients (18.2% vs 90%). In patients with recurrences, the mean time to flare was 28.4 days in the placebo group versus 76.5 days in the anakinra group. IL-1 inhibitors require further research and have the potential to decrease the use of first-line drug regimens for recurrent pericarditis that are not tolerated in specific patient groups.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"273-276"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Presence of Chronic Total Occlusion in Noninfarct-Related Arteries Is Associated With Higher Mortality and Worse Patient Outcomes Following Percutaneous Coronary Intervention for STEMI: A Systematic Review, Meta-Analysis and Meta-Regression. 非梗死相关动脉出现慢性全闭塞与 STEMI 经皮冠状动脉介入治疗后较高的死亡率和较差的患者预后有关：一项系统性回顾、元分析和元回归研究。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-03-08 DOI: 10.1097/CRD.0000000000000683

Aman Goyal, Surabhi Maheshwari, Haania Shahbaz, Viraj Shah, Urooj Shamim, Abhigan Babu Shrestha, Samia Aziz Sulaiman, Pauras Mhatre, Amir Humza Sohail, Abu Baker Sheikh, Sourbha S Dani

{"title":"The Presence of Chronic Total Occlusion in Noninfarct-Related Arteries Is Associated With Higher Mortality and Worse Patient Outcomes Following Percutaneous Coronary Intervention for STEMI: A Systematic Review, Meta-Analysis and Meta-Regression.","authors":"Aman Goyal, Surabhi Maheshwari, Haania Shahbaz, Viraj Shah, Urooj Shamim, Abhigan Babu Shrestha, Samia Aziz Sulaiman, Pauras Mhatre, Amir Humza Sohail, Abu Baker Sheikh, Sourbha S Dani","doi":"10.1097/CRD.0000000000000683","DOIUrl":"10.1097/CRD.0000000000000683","url":null,"abstract":"Reperfusion therapy with percutaneous coronary intervention improves outcomes in patients with ST-elevation myocardial infarction. We conducted a meta-analysis to assess the impact of chronic total occlusion (CTO) in noninfarct-related artery on the outcomes of these patients. Comprehensive searches were performed using PubMed, Google Scholar, and EMBASE. The primary endpoint was the 30-day mortality rate, with secondary endpoints including all-cause mortality, repeat myocardial infarction, and stroke. Forest plots were created for the pooled analysis of the results, with statistical significance set at P < 0.05. A total of 19 studies were included in this meta-analysis, with 23,989 patients (3589 in CTO group and 20,400 in no-CTO group). The presence of CTO was associated with significantly higher odds of 30-day mortality [18.38% vs 5.74%; relative risk (RR), 3.69; 95% confidence intervals (CI), 2.68-5.07; P < 0.00001], all-cause mortality (31.00% vs 13.40%; RR, 2.79; 95% CI, 2.31-3.37; P < 0.00001), cardiovascular-related deaths (12.61% vs 4.1%; RR, 2.61; 95% CI, 1.99-3.44; P < 0.00001), and major adverse cardiovascular events (13.64% vs 9.88%; RR, 2.08; 95% CI, 1.52-2.86; P < 0.00001) than the non-CTO group. No significant differences in repeated myocardial infarction or stroke were observed between the CTO and non-CTO groups. Our findings underscore the need for further research on the benefits and risks of performing staged or simultaneous percutaneous coronary intervention for CTO in the noninfarct-related artery in patients with ST-elevation myocardial infarction.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"218-226"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the Silent Intruder: H. pylori's Hidden Link to Ischemic Heart Disease. 揭开无声入侵者的面纱：幽门螺杆菌与缺血性心脏病的隐秘联系。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-03-06 DOI: 10.1097/CRD.0000000000000686

Kanishk Aggarwal, Sandeep Singh, Ankur Singla, Sai Gautham Kanagala, Fnu Anamika, Bhupinder Singh, Priyanka Aggarwal, Rohit Jain

{"title":"Unveiling the Silent Intruder: H. pylori's Hidden Link to Ischemic Heart Disease.","authors":"Kanishk Aggarwal, Sandeep Singh, Ankur Singla, Sai Gautham Kanagala, Fnu Anamika, Bhupinder Singh, Priyanka Aggarwal, Rohit Jain","doi":"10.1097/CRD.0000000000000686","DOIUrl":"10.1097/CRD.0000000000000686","url":null,"abstract":"Cardiovascular disease is the leading cause of death. In addition to the well-known risk factors associated with cardiovascular disease, such as age, diabetes mellitus, smoking, hypertension, and obesity, there has been a growing concern regarding cardiac complications stemming from the Gram-negative bacteria Helicobacter pylori . While H. pylori is most commonly associated with chronic gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric lymphoma, it has also been implicated in extra gastric manifestations, encompassing cardiac, neurologic, ocular, and dermatologic issues. Key virulent factors for coronary artery disease include the vacuolating cytotoxin gene A and the cytotoxin-associated gene A. The most likely pathogenic mechanism of the relationship between H. pylori and coronary artery disease is initiating a chronic inflammatory process associated with infection and the modifications of classic risk factors. These alterations lead to the creation of prothrombotic and procoagulant environments. Here, we review the cardiac manifestations of H. pylori and the underlying pathophysiological mechanisms.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"227-231"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 and Pulmonary Hypertension: An Interesting Dynamic. COVID-19 与肺动脉高压：有趣的动态

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-02-24 DOI: 10.1097/CRD.0000000000000679

Saam Foroshani, Michael Airo, Avi Levine, William H Frishman, Wilbert S Aronow, Gregg M Lanier

{"title":"COVID-19 and Pulmonary Hypertension: An Interesting Dynamic.","authors":"Saam Foroshani, Michael Airo, Avi Levine, William H Frishman, Wilbert S Aronow, Gregg M Lanier","doi":"10.1097/CRD.0000000000000679","DOIUrl":"10.1097/CRD.0000000000000679","url":null,"abstract":"The dynamic between pulmonary hypertension (PH) and COVID-19 has been under investigation since 2020, early in the pandemic. Although the pathophysiology of PH has been well-studied, new discoveries regarding the multisystemic effects of COVID-19 are still being uncovered. The cardiopulmonary effects of COVID-19 have led investigators to inquire about the interplay between these 2 conditions. Several factors are suggested to contribute to an increased risk of developing PH after infection with SARS-CoV-2. This includes cytokine storm, acute respiratory distress syndrome, and fibrotic changes seen in post-COVID-19 lung disease. Additionally, it has been proposed that certain medications used to treat PH may be applied to patients suffering from the cardiopulmonary complications of COVID-19. This review will focus on the interplay between COVID-19 and PH, with a special focus on the risk of developing PH after SARS-CoV-2 infection and the outcomes of patients with preexisting PH who are diagnosed with COVID-19. The potential benefits of utilizing off-label PH medications for COVID-19 patients will also be discussed.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"199-203"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139943898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of Terlipressin in Hepatorenal Syndrome: Targeting Endothelial Dysfunction and Subsequent Cardiovascular Adverse Events. 肝肾综合征中的特利加压素综述：针对内皮功能障碍和后续心血管不良事件。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-05-01 Epub Date: 2024-06-04 DOI: 10.1097/CRD.0000000000000697

Adrienne M Bielawski, William H Frishman

{"title":"A Review of Terlipressin in Hepatorenal Syndrome: Targeting Endothelial Dysfunction and Subsequent Cardiovascular Adverse Events.","authors":"Adrienne M Bielawski, William H Frishman","doi":"10.1097/CRD.0000000000000697","DOIUrl":"10.1097/CRD.0000000000000697","url":null,"abstract":"Hepatorenal syndrome (HRS) is a serious complication of decompensated liver cirrhosis that results in acute kidney injury (AKI). The mortality rate is high. Endothelial dysfunction secondary to liver cirrhosis is a key driver of the development of portal hypertension, which is eventually complicated by ascites and HRS. Ultimately, splanchnic vasodilation and excess gut lymph production result in ascites, low effective arterial blood volume, and maladaptive compensatory mechanisms that contribute to renal hypoperfusion and injury. While the only curative treatment is liver transplantation, vasoconstrictors and albumin have been the mainstay of treatment for candidates who are ineligible or waiting for transplantation. On September 14, 2022, terlipressin, a V 1 vasopressin receptor agonist, was approved by the Food and Drug Administration for the treatment of HRS-AKI. In clinical trials, terlipressin plus albumin have been superior to albumin alone and equivocal to noradrenaline plus albumin in renal function improvement. Terlipressin, however, does not improve survival, is costly, and is associated with severe adverse events-including severe cardiac and vascular complications. The aim of this review is to provide an overview of terlipressin pharmacology, adverse events-with a focus on cardiovascular complications-and comparative randomized controlled trials that resulted in the Food and Drug Administration's approval of terlipressin. New literature since its approval and ongoing clinical trials will also be highlighted.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"277-285"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0